Fig. 1

CAR-T-38 therapy regimen and treatment response among 6 relapsed AML patients post-allo-HSCT. a Schematic of the CAR-T-38 structure. b Schematic of the CAR-T-38 therapy regimen (* and ** supplementary file). c Variation in donor chimerism in the bone marrow (BM) and peripheral blood (PB) was measured by short tandem repeat-polymerase chain reaction (STR-PCR). d Patients 1, 2, 4, and 5 achieved complete remission (CR) or CR with incomplete count recovery (CRi) at 4 weeks after CAR-T-38 infusion. Patients 1 and 4 relapsed within six months. Patient 4 experienced relapse 117 days after the first CAR-T-38 infusion but exhibited remission after the second CAR-T-38 treatment. The 6-month OS and LFS rates were both 50%. CD38-positive blasts were reduced, and CD38-positive granulocytes and monocytes gradually increased at 1 and 4 weeks after CAR-T-38 infusion. e The CD38-positive blast population is shown in the upper right (red) of the CD34/CD38 plot. f, g CD38-positive granulocytes and monocytes, based on forward versus side scatter and CD38 expression, are shown in the upper left (crimson) and the lower left (green), respectively